

Resource Summary Report

Generated by [dkNET](#) on Sep 14, 2026

NCI-H1993

RRID:CVCL_1512

Type: Cell Line

Proper Citation

RRID:CVCL_1512

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1512

Proper Citation: RRID:CVCL_1512

Description: Cell line NCI-H1993 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Lung adenocarcinoma

Defining Citation: [PMID:8806092](#), [PMID:10987304](#), [PMID:11030152](#), [PMID:16187286](#), [PMID:18083107](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20679594](#), [PMID:22961666](#), [PMID:24297535](#), [PMID:25877200](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29681454](#), [PMID:30038707](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31803961](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H1993

Synonyms: H1993, H-1993, NCIH1993

Cross References: CLO:CLO_0008036, EFO:EFO_0002272, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-3610, ATCC:CRL-5909, BioGRID_ORCS_Cell_line:959, BioSample:SAMN03473255, cancercellines:CVCL_1512, Cell_Model_Passport:SIDM00758, ChEMBL-Cells:ChEMBL3308138, ChEMBL-Targets:ChEMBL1075527, CLS:305463, Cosmic:687809, Cosmic:877248, Cosmic:903608, Cosmic:908476, Cosmic:980988, Cosmic:1032460, Cosmic:1146895,

Cosmic:1694669, Cosmic:1870266, Cosmic:1891898, Cosmic:1995549, Cosmic:2125239, Cosmic:2630415, Cosmic-CLP:908476, DepMap:ACH-001137, EGA:EGAS00001000978, GDSC:908476, GEO:GSM62328, GEO:GSM108831, GEO:GSM108832, GEO:GSM274706, GEO:GSM434315, GEO:GSM513952, GEO:GSM514337, GEO:GSM794341, GEO:GSM817095, GEO:GSM1670204, IARC_TP53:21550, IGRhCellID:NCIH1993, LINCX_LDP:LCL-1646, NCI-DTP:NCI-H1993, PharmacDB:NCIH1993_1054_2019, PRIDE:PXD030304, Progenetix:CVCL_1512, PubChem_Cell_line:CVCL_1512, Wikidata:Q54907897

ID: CVCL_1512

Record Creation Time: 20220427T220838+0000

Record Last Update: 20260913T004953+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H1993.

No alerts have been found for NCI-H1993.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 23 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Yang Y, et al. (2026) Oligodendrocyte-secreted ERBB3 Mediates the Competitive Uptake of Copper Ions by Tumor Cells to Promote Brain Metastasis in Lung Cancer. International journal of biological sciences, 22(7), 3580.

Brunner JS, et al. (2026) Aspartate availability drives differential engagement of the malate-aspartate shuttle. Molecular cell, 86(5), 954.

Del Rey-Vergara R, et al. (2025) MET pathway inhibition increases chemo-immunotherapy efficacy in small cell lung cancer. Cell reports. Medicine, 6(7), 102194.

Miglio U, et al. (2025) Inhibition of the LINE1-derived MET transcript induces apoptosis and oncoprotein knockdown in cancer cells. Molecular therapy. Nucleic acids, 36(2), 102529.

Galan-Cobo A, et al. (2025) KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer. Cancer cell, 43(8), 1530.

Poliaková Turan M, et al. (2024) E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network. Cancer research

communications, 4(7), 1863.

Verdura S, et al. (2024) Silibinin is a suppressor of the metastasis-promoting transcription factor ID3. *Phytomedicine : international journal of phytotherapy and phytopharmacology*, 128, 155493.

Martin-Vega A, et al. (2024) ASCL1 Restrains ERK1/2 to Promote Survival of a Subset of Neuroendocrine Lung Cancers. *Molecular cancer therapeutics*, 23(12), 1789.

Pelos G, et al. (2024) Fast proliferating and slowly migrating non-small cell lung cancer cells are vulnerable to decitabine and retinoic acid combinatorial treatment. *International journal of cancer*, 154(6), 1029.

Torres-Martínez S, et al. (2024) Soluble galectin-3 as a microenvironment-relevant immunoregulator with prognostic and predictive value in lung adenocarcinoma. *Molecular oncology*, 18(1), 190.

Dimitrov J, et al. (2024) Dynamic roles of neutrophil extracellular traps in cancer cell adhesion and activation of Notch 1-mediated epithelial-to-mesenchymal transition in EGFR-driven lung cancer cells. *Frontiers in immunology*, 15, 1470620.

Yoon SJ, et al. (2023) Comprehensive Metabolic Tracing Reveals the Origin and Catabolism of Cysteine in Mammalian Tissues and Tumors. *Cancer research*, 83(9), 1426.

Martin-Vega A, et al. (2023) ASCL1-ERK1/2 Axis: ASCL1 restrains ERK1/2 via the dual specificity phosphatase DUSP6 to promote survival of a subset of neuroendocrine lung cancers. *bioRxiv : the preprint server for biology*.

Köferle A, et al. (2022) Interrogation of cancer gene dependencies reveals paralog interactions of autosome and sex chromosome-encoded genes. *Cell reports*, 39(2), 110636.

Yang L, et al. (2022) Glycosylated Cathepsin V Serves as a Prognostic Marker in Lung Cancer. *Frontiers in oncology*, 12, 876245.

Orlando E, et al. (2022) An oncogene addiction phosphorylation signature and its derived scores inform tumor responsiveness to targeted therapies. *Cellular and molecular life sciences : CMLS*, 80(1), 6.

Yenerall P, et al. (2021) Lentiviral-Driven Discovery of Cancer Drug Resistance Mutations. *Cancer research*, 81(18), 4685.

Bosch-Barrera J, et al. (2021) Silibinin Suppresses Tumor Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung Cancer. *Cancers*, 13(16).

Listunov D, et al. (2021) Development of potent dimeric inhibitors of GAS41 YEATS domain. *Cell chemical biology*, 28(12), 1716.

Kang YP, et al. (2021) Non-canonical Glutamate-Cysteine Ligase Activity Protects against Ferroptosis. *Cell metabolism*, 33(1), 174.